CREATE Medicines announces $122 million Series B financing to advance in vivo CAR pipeline in autoimmune disease and oncology May 18, 2026 Categories: Health Care Tags: CREATE Medicines
CREATE Medicines doses first patient in phase 1/2 Study of MT-304, a first-in-class multi-immune in vivo CAR therapy targeting HER2-positive solid tumors May 8, 2026 Categories: Health Care Tags: CREATE Medicines
CREATE Medicines strengthens executive team with appointment of veteran biopharma leader Allan L. Shaw as CFO and CBO October 9, 2025 Categories: Health Care Tags: CREATE Medicines
Myeloid Therapeutics rebrands as CREATE Medicines, focused on transforming immunotherapy through RNA-based in vivo multi-immune programming October 9, 2025 Categories: Health Care Tags: CREATE Medicines
